December 10th 2023
Although the use of bridging therapy prior to treatment with axicabtagene ciloleucel did not improve efficacy or safety outcomes for patients with relapsed/refractory large B-cell lymphoma, responses to bridging therapy may be prognostic of favorable outcomes after axi-cel administration.
November 30th 2023
November 27th 2023
40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board